Sigyn Therapeutics (SIGY) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Market Cap: $74KFounded: 2019HQ: San Diego, United States

Sector Ranking#142 in Drug Delivery & Formulation

Overview

Sigyn Therapeutics is a public, clinical-stage medical device company developing the Sigyn CardioDialysis™ system, a blood purification technology targeting inflammatory and lipid drivers of cardiovascular disease. Founded in 2019, the company's core strategy is to leverage the established dialysis clinic network for potential commercialization, aiming to address a significant unmet need in MACE reduction. Recent corporate activity indicates the company is actively exploring strategic alternatives, including mergers and asset sales, to advance its technology. Leadership includes Chairman & CEO Jim Joyce, an experienced inventor who previously founded Aethlon Medical and secured FDA Breakthrough Device designations.

Cardiovascular DiseaseOncology

Technology Platform

The Sigyn CardioDialysis™ system is a broad-spectrum, extracorporeal blood purification device designed for the concurrent removal of pro-inflammatory cytokines and cholesterol-transporting lipoproteins from circulation.

Funding History

1

SeedUndisclosedUndisclosedJun 15, 2020

Opportunities

Sigyn targets a ~$100 billion market for MACE reduction by addressing residual inflammatory and lipid risk unmet by drugs.

Its 'plug-and-play' design for existing dialysis clinics offers a capital-efficient path to rapid commercialization in over 7,500 U.S.

sites if clinical efficacy is proven.

Risk Factors

The company faces severe financial liquidity risk and is actively seeking mergers or asset sales to survive.

The core technology is unproven in pivotal outcomes trials, and future success depends on overcoming significant clinical, regulatory, and commercialization hurdles in a competitive landscape.

Competitive Landscape

Sigyn competes indirectly with advanced lipid-lowering and anti-inflammatory drugs, and directly with extracorporeal blood purification devices from firms like CytoSorbents and B. Braun. Its differentiation lies in concurrent cytokine/lipoprotein targeting and a specific integration strategy for chronic outpatient care in dialysis clinics.